The rational use of potentially hepatotoxic medications in patients with underlying liver disease (Q35194515)

7 August 2017

1 reference

title

The rational use of potentially hepatotoxic medications in patients with underlying liver disease (English)

1 reference

7 August 2017

1 reference

James H Lewis

1

1 reference

PubMed ID

12904150

7 August 2017

language of work or name

English

0 references

publication date

1 July 2002

1 reference

Expert Opinion on Drug Safety

7 August 2017

1 reference

7 August 2017

1

1 reference

7 August 2017

159-172

1 reference

7 August 2017

2

1 reference

Epidemiology and individual susceptibility to adverse drug reactions affecting the liver

7 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Management of drug-induced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Drug-induced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Surgery in the patient with liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Anticonvulsant hypersensitivity syndrome: incidence, prevention and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Felbamate in epilepsy therapy: evaluating the risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Drug- and chemical-induced cholestasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Anti-inflammatory drugs and variceal bleeding: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Effect of maximal daily doses of acetaminophen on the liver of alcoholic patients: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

The effect of alcohol on acetaminophen hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Acute versus chronic alcohol consumption in acetaminophen-induced hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Mechanisms of hepatic transport of drugs: implications for cholestatic drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Oral Contraceptives in Acute Viral Hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

The risks of oral contraceptive pills

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Drugs and steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Hepatocellular carcinoma after long-term tamoxifen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Chemoprevention of breast cancer by tamoxifen: risks and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Fulminant liver failure associated with flutamide therapy for hirsutism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Troglitazone (Rezulin) and hepatic injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Failure to develop hepatic injury from rosiglitazone in a patient with a history of troglitazone-induced hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Hepatotoxicity of antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Trovafloxacin hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Anti-tuberculous therapy and acute liver failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Safety of an ofloxacin-based antitubercular regimen for the treatment of tuberculosis in patients with underlying chronic liver disease: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Treatment of pruritus of primary biliary cirrhosis with rifampin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Hepatic decompensation associated with lamivudine: a case report and review of lamivudine-induced hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Risk of HAART therapy in hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Drug treatment of lipid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

HMG-CoA reductase inhibitors and myotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Comparative tolerability of the HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Safety of fenofibrate--US and worldwide experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Labetalol hepatotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Pemoline hepatotoxicity and postmarketing surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Effect of cyclosporine on bile secretion in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Herbal products for liver diseases: a therapeutic challenge for the new millennium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Complementary and alternative medicine in chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

21 January 2018

Herbal hepatotoxicity

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Liquorice and its health implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Pharmacogenetics and adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Accuracy of hepatic adverse drug reaction reporting in one English health region

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Metformin in non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.2.159

21 January 2018

Identifiers

DOI

10.1517/14740338.1.2.159

1 reference

7 August 2017

1 reference

PubMed ID

12904150